Sino Biopharmaceutical Ltd traded at 5.26 this Thursday July 7th, increasing 0.07 or 1.35 percent since the previous trading session. Looking back, over the last four weeks, Sino Biopharmaceutical Ltd gained 24.35 percent. Over the last 12 months, its price fell by 25.18 percent. Looking ahead, we forecast Sino Biopharmaceutical Ltd to be priced at 4.74 by the end of this quarter and at 4.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Cspc Pharmaceutical 8.01 -0.14 -1.72% -20.69%
Jiangsu Hengrui Me. 38.65 -0.77 -1.95% -37.02%

Indexes Price Day Year
HK50 21644 56.92 0.26% -20.29%

Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.